Your browser doesn't support javascript.
loading
SpaceOAR hydrogel spacer injection prior to stereotactic body radiation therapy for men with localized prostate cancer: A systematic review.
Payne, Heather A; Pinkawa, Michael; Peedell, Clive; Bhattacharyya, Samir K; Woodward, Emily; Miller, Larry E.
Afiliação
  • Payne HA; Oncology Department, University College London Hospital, London, UK.
  • Pinkawa M; Department of Radiation Oncology, MediClin Robert Janker Klinik, Bonn, Germany.
  • Peedell C; James Cook University Hospital, Middlesbrough, UK.
  • Bhattacharyya SK; Health Economics and Market Access, Boston Scientific, Marlborough, MA.
  • Woodward E; Boston Scientific AG, Ecublens, Switzerland.
  • Miller LE; Department of Biostatistics, Miller Scientific, Johnson City, TN.
Medicine (Baltimore) ; 100(49): e28111, 2021 Dec 10.
Article em En | MEDLINE | ID: mdl-34889268
BACKGROUND: Conventionally fractionated radiotherapy is a common treatment for men with localized prostate cancer. A growing consensus suggests that stereotactic body radiation therapy (SBRT) is similarly effective but less costly and more convenient for patients. The SpaceOAR hydrogel rectal spacer placed between the prostate and rectum reduces radiation-induced rectal injury in patients receiving conventionally fractionated radiotherapy, but spacer efficacy with SBRT is unclear. The purpose of this research was to assess the clinical utility of the hydrogel rectal spacer in men receiving SBRT for prostate cancer. METHODS: We performed systematic searches of Medline, Embase, and the Cochrane Central Register of Controlled Trials for studies in men who received the SpaceOAR hydrogel spacer prior to SBRT (≥5.0 Gy fractions) for treatment of localized prostate center. Rectal irradiation results were compared to controls without spacer implant; all other outcomes were reported descriptively owing to lack of comparative data incuding perirectal separation distance, rectal irradiation on a dosimetric curve, gastrointestinal (GI) toxicity, and freedom from biochemical failure. GI toxicity was reported as the risk of a grade 2 or 3+ bowel complication in early (≤3 months) and late (>3 months) follow-up. RESULTS: In 11 studies with 780 patients, SBRT protocols ranged from 7 to 10 Gy per fraction with total dose ranging from 19 to 45 Gy. Perirectal distance achieved with the rectal spacer ranged from 9.6 to 14.5 mm (median 10.8 mm). Compared to controls receiving no spacer, SpaceOAR placement reduced the radiation delivered to the rectum by 29% to 56% across a dosimetric profile curve. In early follow-up, grade 2 GI complications were reported in 7.0% of patients and no early grade 3+ GI complications were reported. In late follow-up, the corresponding rates were 2.3% for grade 2 and 0.3% for grade 3 GI toxicity. Over 16 months median follow-up, freedom from biochemical failure ranged from 96.4% to 100% (pooled mean 97.4%). CONCLUSIONS: SpaceOAR hydrogel spacer placed between the prostate and rectum prior to SBRT is a promising preventative strategy that increases the distance between the prostate and rectum, reduces rectal radiation exposure, and may lower the risk of clinically important GI complications.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Radiocirurgia / Hidrogéis Tipo de estudo: Etiology_studies / Guideline / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Radiocirurgia / Hidrogéis Tipo de estudo: Etiology_studies / Guideline / Systematic_reviews Limite: Humans / Male Idioma: En Ano de publicação: 2021 Tipo de documento: Article